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a b s t r a c t
Heterosexual HIV-1 transmission has been identiﬁed as a genetic bottleneck and a single transmitted/
founder (T/F) variant with reduced sensitivity to type I interferon initiates productive infection in most
cases. We hypothesized that particularly active accessory protein(s) may confer T/F viruses with a
selective advantage in establishing HIV infection. Thus, we tested vpu, vif and nef alleles from six T/F and
six chronic (CC) viruses in assays for 9 immune evasion activities involving the counteraction of
interferon-stimulated genes and modulation of ligands known to activate innate immune cells. All
functions were highly conserved with no signiﬁcant differences between T/F and CC viruses, suggesting
that these accessory protein functions are important throughout the course of infection.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Studies have deﬁned a genetic ‘bottleneck’ at mucosal HIV-1
transmission with a single inferred variant initiating peripheral
viremia in most cases (Baalwa et al., 2013; Fenton-May et al., 2013;
Haaland et al., 2009; Ochsenbauer et al., 2012; Parrish et al., 2013;
Salazar-Gonzalez et al., 2009). In particular it has been noted that
transmitted founder (T/F) Envelope proteins are R5 tropic with both
increased sensitivity to broadly neutralizing antibodies (Wilen et al.,
2011) and reduced ability to interact with maraviroc-bound CCR5
compared to viruses isolated from chronic infection (Parker et al.,
2013). Furthermore, preferential transmission of ancestral as opposed
to contemporary strains in donor individuals has been reported (Redd
et al., 2012), suggesting speciﬁc viral determinants for sexual transmis-
sion that differ from determinants for propagation of chronic infection.
Intriguingly, it has been reported that T/F viruses are less restricted by
interferon (IFN) in primary T cells than chronic controls (Fenton-May
et al., 2013; Parrish et al., 2013).
Lentiviral accessory proteins have evolved the ability to mitigate the
detrimental effects of an IFN-induced antiviral immune response by
interfering with various host immunity factors (Harris et al., 2012; Moll
et al., 2010; Shah et al., 2010). For example, HIV-1 Vpu and Vif
counteract the IFN-inducible restriction factors tetherin/BST-2/CD317
(Neil et al., 2008; Van Damme et al., 2008) and APOBEC3D/F/G,
respectively (Bishop et al., 2004; Hultquist et al., 2011; Sheehy et al.,
2002; Zheng et al., 2004). Vpu also prevents expression of IFN and IFN-
stimulated genes by inhibiting the activation of NF-κB (Bour et al.,
2001; Sauter et al., 2015), and Nef is known tomodulate a range of host
immune receptors including CD4 and MHC molecules (Kirchhoff,
2010).
We hypothesized that accessory gene(s) from T/F viruses confer
advantages to establishment and early propagation of HIV-1 infec-
tion either through counteraction of IFN-stimulated genes or mod-
ulation of ligands known to activate NK, NKT and other immune
cells. We therefore directly compared functional activities of the
accessory proteins Vpu, Vif and Nef from six T/F and six CC viruses
(see Table 1 for patient characteristics and Supplementary Figs. 1–3
for multiple sequence alignments).
Results
Counteraction of tetherin/BST-2/CD317 and NF-κB activation by Vpu
Vpu proteins from T/F and CC viruses were tested for their ability to
increase virion release by counteracting tetherin/BST-2/CD317. Tetherin
serves as a physical tether between viral and cellular membranes and
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inhibits the egress of budding virions from infected cells. All Vpus were
expressed (Fig. 1A) and enabled efﬁcient virus release from tetherin
expressing HEK293T cells. Anti-tetherin activity was similar for Vpus
from T/F and CC viruses (p¼0.51, Fig. 1B), consistent with a previous
study demonstrating conservation of tetherin antagonism over
extended periods in chronically infected patients (Pickering et al.,
2014).
Tetherin does not only restrict virion release but also acts as an
innate sensor activating NF-κB-dependent expression of type I IFN
and IFN-stimulated genes (Galao et al., 2012). We therefore investi-
gated whether T/F Vpus are more efﬁcient in blocking tetherin
signaling than Vpus from CC viruses. A dual luciferase reporter assay
in HEK293T cells revealed that all Vpus efﬁciently inhibited the
activation of NF-κB with no signiﬁcant differences between the T/F
and CC groups (p¼0.81, Fig. 1C). Since Vpu has also been reported to
block activation of NF-κB independently of tetherin (Bour et al.,
2001; Sauter et al., 2015), we repeated the experiment using a
constitutively active mutant of IKKβ instead of tetherin as the
inducer. Again, T/F and CC Vpus suppressed NF-κB activation to
similar degrees (p¼0.31, Fig. 1D).
Cell surface downregulation of CD4, NTB-A and CD1d by Vpu
Besides counteracting tetherin and inhibiting NF-κB activation, Vpu
also decreases cell surface expression of CD4, NTB-A and CD1d. While
downmodulation of CD4 prevents superinfection and enables the
release of fully infectious progeny virions from infected cells (Kimura
et al., 1994; Lama et al., 1999; Wildum et al., 2006), downmodulation
of NTB-A and CD1d has been suggested to protect HIV-1 infected cells
from NK or NKT cell mediated killing, respectively (Moll et al., 2010;
Shah et al., 2010). Using ﬂow cytometry, we monitored expression of
these receptors on the surface of HEK293T cells transfected with Vpu
or a vector control. Vpu reduced surface levels of all three receptors as
expected, without signiﬁcant differences between T/F and CC viruses
(CD4: p¼0.84, NTB-A: p¼0.61, CD1d: p¼0.34, Fig. 1E–J).
Counteraction of APOBEC3F/G by Vif
The accessory protein Vif induces the ubiquitination and subse-
quent degradation of the restriction factors APOBEC3DF/G/H to
prevent their incorporation into viral particles (Bishop et al., 2004;
Hultquist et al., 2011; Sheehy et al., 2002). APOBEC3F/G are cytidine
deaminases, inhibiting HIV-1 replication through G to A hypermuta-
tion of viral cDNA as well as direct inhibition of reverse transcription
itself (Gillick et al., 2013). We analyzed the activity of T/F and CC Vif
proteins against human APOBEC3F and APOBEC3G by co-transfecting
HEK293T cells with plasmids encoding vif-deﬁcient HIV-1 along
with APOBEC3F or APOBEC3G and vif alleles/empty plasmid. As Vif
expression/ stability varied between alleles tested, the amount of Vif
expression plasmid was modiﬁed in order to achieve similar amounts
of Vif protein in the producer cells (Fig. 2A). Under these conditions
the infectivity of supernatant viruses was determined, revealing that
Vifs from T/F and CC viruses have equivalent activity against
APOBEC3F and APOBEC3G (Fig. 2B and C).
Cell surface downregulation of CD4, CD28 and MHC class I by Nef
The accessory protein Nef downregulates various cell surface
proteins including CD4, MHC class I and CD28 to escape immune
surveillance (Garcia and Miller, 1991; Schwartz et al., 1996; Swigut
et al., 2001) and may thus also be involved in the reduced sensitivity
of T/F viruses to IFN. CD4 and CD28 downregulation were analyzed
by transient transfection of HEK293T cells with vectors expressing
Nef and either CD4 or CD28. All Nef proteins were efﬁciently exp-
ressed (Fig. 3A) and reduced surface expression of both receptors
with no signiﬁcant differences between T/F and CC viruses (CD4:
p¼0.71, CD28: p¼0.76, Fig. 3B–E). To explore MHC class I down-
regulation, a HeLa cell line expressing HLA-Bn27 was transfected with
different nef alleles and MHC class I cell surface expression was
analyzed by FACS 48 h post-transfection. Nef proteins of both groups
of viruses downmodulated MHC class I to a similar extent (p¼0.22,
Fig. 3F and G).
Nef-mediated enhancement of virion infectivity
It has been shown that HIV-1 virion infectivity is reduced in the
absence of a functional nef gene (Aiken and Trono, 1995; Chowers et
al., 1994). We thus tested the effect of Nef proteins on virion infectivity
by transfecting HEK293T cells with nef alleles and nef-deﬁcient HIV-1
NL4-3. Supernatants harvested two days post-transfection were used
to infect indicator TZM-bl cells with normalized amounts of p24.
Despite variation between individual Nef proteins in their ability to
enhance virion infectivity, there was no statistical difference when T/F
and CC Nefs were compared (p¼0.77, Fig. 3H).
Discussion
In summary, our results show that established functions of the
accessory proteins Vpu, Vif and Nef are conserved across T/F and
CC viruses. Speciﬁcally, our results from transient expression
studies suggest that the increased IFN resistance of newly trans-
mitted HIV-1 strains is not the result of a particularly efﬁcient
Vpu-mediated inhibition of NF-κB activation or counteraction of
the restriction factors tetherin and APOBEC3F/G. An important
limitation is that viral proteins were not expressed from a provirus
in our experiments, and therefore it is possible that in vivo
expression may differ.
Table 1
Origins and characteristics of viruses used in this study.
Virus Country of origin Gender Transmission route Fiebig stage Viral load at isolation Cd4 count at isolation Coreceptor tropsim TF/CC HIV-1 subtype
ZM246F Zambia F Heterosexual II 10,013,800 NA R5 TF C
ZM247F Zambia F Heterosexual II 10,823,500 NA R5 TF C
ZM249M Zambia M Heterosexual IV 42,000,000 NA R5 TF C
CH040 USA M MSM II 2,197,248 NA R5 TF B
WITO USA M Heterosexual II 325, 064 NA R5 TF B
CH077 USA M MSM II/III 394, 649 NA R5/X4 TF B
CH432 Malawi M Heterosexual NA 40,570 261 R5 CC C
CH457 Tanzania F Heterosexual NA 234,671 450 R5 CC C
CH534 South Africa F Heterosexual NA NA NA NA CC C
RHGA USA M MSM NA 50,000 571 R5 CC B
WARO USA F MSM NA 16,758 598 R5 CC B
STCOr1 USA M MSM NA 67,964 796 R5/X4 CC B
Key: MSM: men who have sex with men; TF – transmitted/founder virus; CC- Chronic virus; NA – not available; Feibig stage as described previously (Fiebig et al., 2003)
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The identiﬁcation of traits that are shared by T/F viruses may
ultimately provide novel targets for strategies aiming to prevent
the acquisition of HIV-1 at mucosal surfaces. Thus, further analyses
of accessory viral gene function in primary human cells and
systematic comparison of other HIV-1 gene products are highly
warranted to decipher the reason(s) for the increased IFN resis-
tance and selection advantage of T/F viruses during transmission
and acute infection.
Materials and methods
Cell culture and transfections
HEK293T, TZM-bl and HeLa.B27 cells were grown under stan-
dard conditions in Dulbecco's Modiﬁed Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum, 120 mg/ml strepto-
mycin, 120 mg/ml penicillin and 2 mM L-glutamine. Cells were
Fig. 1. Vpu-mediated counteraction of tetherin, inhibition of NF-κB activation and downmodulation of CD4, NTB-A and CD1d. (A) Immunoblot showing expression of T/F and
CC Vpu proteins in HEK293T cells transfected with pCG vpu IRES eGFP expression constructs. An antibody against AU-1 was used to detect C-terminally tagged Vpu.
(B) HEK293T cells were co-transfected with expression vectors for HIV-1 Gag-Pol, VSV-G, a modiﬁed HIV genome encoding ﬁreﬂy luciferase, Vpu and tetherin or an empty
vector control. 48 h post-transfection, viral supernatants were used to infect TZM-bl cells and luciferase activity was measured 24 h post-infection. Infectious virus yield in
the presence of Vpu was normalized to that in the presence of empty vector (vector control). (C and D) HEK293T cells were co-transfected with Vpu expression plasmids,
along with plasmid expressing an NF-κB-dependent ﬁreﬂy luciferase reporter construct and a pTAL promoter gaussia luciferase plasmid for normalization, and either a
plasmid expressing (C) human tetherin or (D) a constitutively active mutant of IKKβ. 40 h post- transfection, dual luciferase assays were performed. Fireﬂy luciferase signals
were divided by the corresponding gaussia luciferase signals and normalized to the vector control. (E–J) HEK293T cells were transfected with (E and F) CD4 (G and H) NTB-A
or (I and J) CD1d expression vectors and plasmids expressing eGFP alone or together with Vpu. Two days post-transfection CD4, NTB-A or CD1d surface expression was
detected by ﬂuorophore-conjugated antibodies and examined by ﬂow cytometry. Mean ﬂuorescence intensities were normalized to the control construct expressing only
eGFP (vector control). Each data point represents one vpu allele. The mean of three independent experiments 7 sd is shown. In all experiments, unpaired Student's t test was
performed to examine differences between T/F and CC viruses. (E,G and I) Examples of primary experimental data from ﬂow cytometry for one T/F and CC Vpu.
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transfected using the calcium-phosphate precipitation method,
polyethyleneimine (PEI) or Fugene 6 (Roche Applied Science).
Expression vectors
Vpu, Nef, CD1d, CD4, NTB-A (transcript variant 2) and BST-2/
tetherin alleles were cloned into the CMV-promoter-based pCG
expression vector, vpu and nef encoding vectors co-expressing eGFP
or DsRed via an IRES as previously described (Sauter et al., 2009).
CD28 was cloned into in a pcDNA3.1þ vector. HA-tagged subtype B
and C Vif alleles were ampliﬁed from transmitted/founder and
chronic full-length IMCs (infectious molecular clones) kindly provided
by Beatrice Hahn and cloned into pcDNA3.1 using NotI and XhoI
restriction sites. The plasmids encoding T7-A3F/G have been pre-
viously described (Apolonia et al., 2015). The ﬁreﬂy luciferase reporter
plasmid containing three NF-κB binding sites as well as the consti-
tutively active mutant of IKKβ were kindly provided by Bernd
Baumann. A minimal promoter gaussia luciferase construct was
purchased from Clontech (#631909) and used for normalization. It
contains the TATA-like promoter (pTAL) region from the Herpes
simplex virus thymidine kinase (HSV-TK) that is not responsive to
NF-κB.
Western blotting
Protein expression was assessed by standard immunoblots using
anti AU-1 antibody (bs-2114R, Bioss) to detect AU1 tagged Vpu and
Nef proteins or anti HA (3F10, Roche) to identify HA-tagged Vif. Anti-
HSP90 (H114, Santa Cruz Biotechnology) and anti-actin antibody
(AC-15, Abcam) were used to detect the loading control proteins.
Flow cytometry
To determine the effect of Vpu on CD1d or NTB-A, HEK293T cells
were transfected with 1 μg of the CD1d or NTB-A expression vector
and 5 μg of pCG_IRES eGFP constructs expressing eGFP alone or
together with Vpu. Two days post-transfection CD1d or NTB-A
expression was examined by FACS analysis, essentially as described
previously (Sauter et al., 2013). A phycoerythrin-conjugated anti-
CD1d antibody (BD 550255) or an APC-conjugated anti-SLAM6
antibody (R&D FAB19081A) were used for staining. Fluorescence of
stained cells was detected by two-color ﬂow cytometry and Vpu-
mediated down-modulation of the respective protein was calculated.
Brieﬂy, the mean ﬂuorescence intensities were determined for cells
showing speciﬁc ranges of eGFP expression. The ﬂuorescence values
obtained for cells transfected with the control construct expressing
only eGFP was compared with the corresponding number obtained
for cells coexpressing Vpu and eGFP to determine the efﬁciency of
CD1d or NTB-A down-modulation.
To determine the effect of Vpu and Nef on CD4, HEK293T cells
were transfected with 0.05 μg of the CD4 expression vector and
0.15 μg of pCG_IRES eGFP constructs expressing eGFP alone or
together with Vpu or Nef. Two days post- transfection CD4 expres-
sion was examined by FACS analysis. A PE/Cy5 anti-human CD4
Antibody (BioLegend) was used for staining. Fluorescence of stained
cells was detected by two-color ﬂow cytometry and quantiﬁed as
described above.
To determine the effect of Nef on CD28, HEK293T cells were
transfected with 1 μg of the CD28 expression vector and 0.15 μg of
pCG_IRES eGFP constructs expressing eGFP alone or together with
Nef. Two days post-transfection CD28 expression was examined
by FACS analysis. APC-conjugated anti-human CD28 antibody
(CD28.2, BD Biosciences) was used for staining.
To determine the effect of Nef on MHC I, HeLa.B27 cells [a kind gift
from Anthony Antoniou] were transfected with 0.5 μg of pCG_IRES
eGFP constructs expressing eGFP alone or together with Nef. Two days
post-transfection MHC I expression was examined by FACS analysis. A
PE/Cy5 anti-human HLA-A,B,C antibody, cloneW6/32 (BioLegend) was
used for staining. Fluorescence of stained cells was detected by two-
color ﬂow cytometry and quantiﬁed as described above.
NF-κB reporter assay
Transfections for luciferase assays were performed in 96-well
plates and each transfection was performed in triplicate as described
before (Sauter et al., 2013). Brieﬂy, Vpu expression plasmids (100 ng)
were transfected in HEK293T cells along with a plasmid expressing
human tetherin or a constitutively active mutant of IKKβ (40 ng),
an NF-κB-dependent ﬁreﬂy luciferase construct (100 ng) and a pTAL
promoter gaussia luciferase reporter plasmid (25 ng). 40 h post-
transfection, dual luciferase assays were performed. Fireﬂy luciferase
signals were normalized to the corresponding gaussia luciferase
signals.
Luciferase reporter virus assay
HEK293T cells were co-transfected with 0.3 μg of p8.91 HIV-
1 gag-pol expression vector, 0.3 μg VSV-G, and 0.45 μg of
Fig. 2. Vif-mediated counteraction of APOBEC3F and APOBEC3G. HEK293T cells were transfected with plasmids encoding NL4-3 Δvif, APOBEC3F or G and HA-tagged Vif
proteins. 48 h post-transfection, producer cells and supernatants were harvested. (A) Expression of Vif proteins in producer cells was assessed by standard immunoblot.
(B and C) Virion infectivity of supernatants generated in the presence of APOBEC3F (B) or APOBEC3G (C) was determined using TZM-bl indicator cells. Luciferase values were
normalized to controls without Vif (vector control). The mean of four independent replicates 7sd is shown.
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pCSLUCW retroviral expression vector encoding luciferase. For
tetherin counteraction experiments, 0.25 μg of T/F or CC Vpu
constructs were co-transfected with 0.05 μg of tetherin, or
empty vector (pcDNA3.1). 48 h post-transfection, viral super-
natants were harvested, ﬁltered using 0.45 mm pore-sized ﬁlters
and used to infect TZM-bl cells. Luciferase activity of the TZM-bl
cells was measured 24 h post-infection using the Steady Glo
Fireﬂy Luciferase assay (Promega) and GloMax96 Luminometer
(Promega).
Nef infectivity assay
HEK293T cells were cotransfected with 0.4 μg pBR_HIV-1 M
NL4-3 (nef STOP) and 2 μg of pCG_Nef IRES eGFP in six well plates
Fig. 3. Nef-mediated downmodulation of CD4, CD28, MHC class I and enhancement of virion infectivity. (A) Immunoblot showing expression of T/F and CC Nef proteins in
HEK293T cells transfected with pCG_nef IRES eGFP expression constructs. An antibody against AU-1 was used to detect C-terminally tagged Nef. (B–E) HEK293T cells were
transfected with (B and C) CD4 or (D and E) CD28 expression vector and constructs expressing eGFP alone or together with Nef. Two days post-transfection CD4 or CD28
expression was detected by ﬂow cytometry. Mean ﬂuorescence intensities were normalized to the control construct expressing only eGFP (vector control). (F and G) MHC
class I downregulation using HeLa.B27 cells transfected with constructs expressing eGFP alone or together with Nef. Two days post-transfection MHC I expression was
analyzed by ﬂow cytometry as described above. (H) Virion infectivity enhancement by Nef was measured using HEK293T cells co-transfected with HIV-1 NL4-3 and eGFP Nef.
Supernatants were harvested 48 h post-transfection and p24-normalized virus was used to infect TZM-bl cells. Infectivity was normalized to the control construct expressing
no nef allele (vector control). The mean of at least three independent experiments 7sd is shown. (B,D and F) Example of primary experimental data from ﬂow cytometry for
one T/F and CC Nef.
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using the Calcium phosphate method. Virus was harvest from
supernatant 48 h post-transfection and normalized using p24Gag
ELISA. Normalized virus was used to infect indicator TZM-bl cells
and β-galactosidase activity measured 72 h post-infection using
Gal-screen substrate (Applied Biosystems, USA).
A3F/G restriction assay
HEK293T cells were co-transfected with vif-deﬁcient NL4-3
(Phalora et al., 2012) and T7-A3F/G (Apolonia et al., 2015) at a 1:1
ratio. Cells were also co-transfected with plasmids encoding HA-
tagged Vif proteins from T/F and CC viruses. 48 h after transfection,
supernatants containing viruses were harvested, ﬁltrated through a
45 μm pore-sized ﬁlter and quantiﬁed using a p24Gag ELISA (Perkin
Elmer). Viruses were then used to infect indicator TZM-bl cells and
luciferase activity was measured 48 h post-infection. Producer cells
were lysed in RIPA buffer (50 mM Tris–HCl pH 7.4, 100 mM NaCl,
1 mM MgCl2, 1% NP-40, 0.1% SDS and 0.5% sodium deoxycholate).
Protein expression was assessed by standard immuno blot, anti HA
(3F10, Roche) to identify HA-tagged Vif and anti-HSP90 (H114, Santa
Cruz Biotechnology). Proteins were then detected by Li-cor Odyssey
infrared imaging using IRDye800CW or IRDye 680LT-labeled second-
ary antibodies.
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